Acacia Pharma plans to raise about 150 million pounds ($232 million) by selling new shares in an initial public offering to fund the development of four medicines designed to quell post-surgery and post-chemotherapy symptoms such as vomiting for cancer patients.
The drugmaker, founded in 2007 in Cambridge, England, will have at least 25 percent of its stock trading on the London Stock Exchange after the sale in October, it said in a statement on Monday. Acacia may sell another 15 percent if there’s demand.
The company didn’t specify the number of shares it will sell or the price it’s seeking, though a spokesperson said the company aims to raise 150 million pounds.
The proceeds will help bring the company’s two lead products, nausea drugs in mid-stage and advanced clinical research, to market, the company said.
“Acacia Pharma has a strong pipeline of four product candidates and a clear plan to market them through our own U.S. sales organization,” CEO Julian Gilbert said in the statement. “I am excited by the prospect of the growth that can be supported by the planned IPO.”
Before co-founding Acacia, Gilbert was co-founder and commercial director of Arakis, which was sold to Sosei Group in 2005 for 107 million pounds ($165 million).
JPMorgan Chase & Co is managing the IPO along with Canaccord Genuity.
Since its founding, Acacia has raised about 35 million pounds from Lundbeckfond Invest, Novo, Beacon Bioventures Fund III Partnership and Gilde Healthcare Partners.
These materials are not intended and should not be used as legal advice or other recommendation. If you need a legal opinion on a specific issue or factual situation, please contact a lawyer. Anyone using these materials should not rely on them as a substitute for legal advice.
Consulting CWIIL Group of Companies, for any / all investment matters ensures advice based on highest level of knowledge which are given to you by a team of select research-oriented experts whom each will do their own assessment of your matter, and also assess it together, thus ensuring that in case a mistake has been made by one, it will be noticed and corrected even before it is being passed on to you. Receiving incorrect and un-knowledgeable investment advice can be disastrous and thus should be avoided.
Remember, no problem has a quick fix solution. Thus, always ensure to consult highly knowledgeable group of professionals whom would provide you with a collective advice, never individual advice. This group advice and approach is unique with CWIIL Group and is based on the overall Management Philosophy of all CWIIL Group Companies.
CWIIL Group of Companies is a global group of multi-specialized units with diversified interests and activities, wherein each company is a separate legal entity registered under prevailing laws in different parts of the world. CWIIL Group of Companies Products, Services, Project and Solutions are in a multitude of Verticals including, but not limited to, Infrastructure, Power, Oil & Gas, Legal, Media, Technology, ITES, HR, Shipping, Aviation, Real Estate, Hospitals, Health and Medicine, Education, Funding & Investment, Business and Legal Consultancy, and Public Private Partnerships, and other CWIIL Group Units, worldwide, to name a few.
For Further Queries Feel Free to Contact :
For Any / All Other Queries :
CWIIL Group Global Regional Headquarters Denmark,
Address : No. 1, Klokkebjergevej, DK6900 Skjern, Denmark
Voice : +45.5148.3608
Fax : +45.7014.1498
Email : firstname.lastname@example.org
Web : www.cwiilgroup.eu
Connect : LinkedIn – Twitter – Facebook – Quora
Office Hours :
Monday to Friday : 10.00 – 17.00 CET.
Saturday : 10.00 – 14.00 CET.
Sunday : Closed.
The Corporate Communications Team would require minimum a fortnight for Reviewing & Responding to Queries, which please note.